CML

Novartis signs agreement with UN-backed Medicines Patent Pool to license generics of its CML drug
Novartis signs agreement with UN-backed Medicines Patent Pool to license generics of its CML drug
CP WIre
Novartis
Tasigna
generics
nilotinib
CML
Medicines Patent Pool
Flag link:
Novartis signs agreement with UN-backed Medicines Patent Pool to license generics of its CML drug
Novartis
Tasigna
generics
nilotinib
CML
Medicines Patent Pool
Flag link:
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data
Fierce Pharma
ASCO 2022
Novartis
Gleevec
Scemblix
CML
chronic myeloid leukemia
Flag link:
FDA Approves Scemblix for Pretreated CML in the Chronic Phase
FDA Approves Scemblix for Pretreated CML in the Chronic Phase
Cure Today
Novartis
Scemblix
FDA
CML
Flag link:
ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival
ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival
Endpoints
ASH2020
Novartis
CML
asciminib
Pfizer
Flag link:
ASH: Takeda pads case for new leukemia use with 5-year survival data
ASH: Takeda pads case for new leukemia use with 5-year survival data
Fierce Pharma
Takeda
ASH2020
CML
Iclusig
Flag link:
Xspray Pharma reports positive clinical data for HyNap-Dasa product candidate
Xspray Pharma reports positive clinical data for HyNap-Dasa product candidate
Pharmaceutical Business Review
Xspray Pharma
clinical trials
HyNap-Dasa
CML
chronic myeloid leukemia
Flag link:
Pfizer's blood cancer drug Bosulif effective in untreated patients
Pfizer's blood cancer drug Bosulif effective in untreated patients
Yahoo/Reuters
Pfizer
Bosulif
chronic myeloid leukemia
CML
Flag link:
2 Pharmas That Should Move After 55th ASH Meeting
2 Pharmas That Should Move After 55th ASH Meeting
Seeking Alpha
ASH
Iclusig
Ariad Pharmaceuticals
SL-401
CML
Stemline
Flag link:
Ariad Pharmaceuticals Plummets 70% as Drug Trial Held
Ariad Pharmaceuticals Plummets 70% as Drug Trial Held
Barron's
Ariad Pharmaceuticals
Iclusig
CML
Flag link:
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Seeking Alpha
Gleevec
Ariad Pharmaceuticals
Iclusig
CML
Novartis
chronic myeloid leukemia
Flag link:
2 Biotech Companies With Strong Product Launches To Monitor
2 Biotech Companies With Strong Product Launches To Monitor
Seeking Alpha
Uceris
Santarus
ulcerative colitis
Iclusig
Ariad Pharmaceuticals
CML
chronic myeloid leukemia
Flag link:
Does Ariad's Leukemia Drug Have Hidden Potential?
Does Ariad's Leukemia Drug Have Hidden Potential?
Motley Fool
Ariad Pharmaceuticals
Iclusig
chronic myeloid leukemia
CML
Flag link:
Doctors blast ethics of $100,000 cancer drugs
Doctors blast ethics of $100,000 cancer drugs
CNN Money
physicians
drug pricing
CML
Gleevec
Novartis
Flag link:
Pfizer's Oncology Division Gets A Boost With European Approval For Bosulif
Pfizer's Oncology Division Gets A Boost With European Approval For Bosulif
Seeking Alpha
Pfizer
oncology
Bosulif
CML
Flag link:
Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine
Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine
TheStreet.com
CML
Ariad Pharmaceuticals
Iclusig
Flag link:
The Survey Says: Ariad's Leukemia Drug Is Toxic
The Survey Says: Ariad's Leukemia Drug Is Toxic
TheStreet.com
Ariad Pharmaceuticals
CML
Iclusig
Flag link:
ARIAD Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML
ARIAD Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML
Seeking Alpha
Ponatinib
CML
Ariad Pharmaceuticals
Pfizer
Bristol-Myers Squibb
Novartis
Flag link:
Medco, MolecularMD team on CML test
Medco, MolecularMD team on CML test
Medco
CML
Flag link: